Ovarian-Protective Effects of Clotrimazole on Ovarian Ischemia/Reperfusion Injury in a Rat Ovarian-Torsion Model
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Clotrimazole treatment reduced serum malondialdehyde, ischemia-modified albumin, and total oxidant status in a rat model of ovarian ischemia/reperfusion injury.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND/AIMS: To evaluate the ovarian-protective effects of clotrimazole on ovarian ischemia/reperfusion injury in a rat ovarian-torsion model. METHODS: 32 Sprague-Dawley rats were randomly divided into four groups: (1) ischemia group (n = 8) in which only left adnexal torsion was performed for 2 h, but no treatment was given; (2) vehicle group (n = 8) in which left adnexal torsion was performed for 2 h and at the end of 2 h ischemia polyethylene glycol (3% PEG, 1 ml, i.p.) was administered and a 24-hour reperfusion was continued; (3) clotrimazole group (n = 8) in which left adnexal torsion was performed for 2 h and at the end of 2 h ischemia clotrimazole (30 mg/kg, i.p.) was administered and a 24-hour reperfusion was continued, and (4) control group (sham-operated, n = 6) in which no adnexal torsion and no treatment were given. The criteria for ovarian ischemia were follicular cell degeneration, vascular congestion, hemorrhage and infiltration by inflammatory cells. Each specimen was scored for each criterion (0, none; 1, mild; 2, moderate; 3, severe). RESULTS: Clotrimazole significantly decreased plasma levels of serum malondialdehyde, ischemia-modified albumin, and total oxidant status. CONCLUSION: This study showed the ovarian-protective effects of clotrimazole on ovarian ischemia/reperfusion injury.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (18)
- Torsion of the previously normal uterine adnexa via openalex
- doi:10.1016/j.clinbiochem.2005.08.008 via openalex
- doi:10.1111/j.1442-200x.2005.02137.x via openalex
- doi:10.1016/j.cardiores.2004.02.012 via openalex
- doi:10.3109/10715768909087918 via openalex
- doi:10.1093/humrep/deq378 via openalex
- doi:10.1016/s0306-4522(02)00164-1 via openalex
- doi:10.1111/j.1469-7793.1998.777bp.x via openalex
- doi:10.1016/j.clinbiochem.2003.10.014 via openalex
- doi:10.1016/0006-2952(87)90694-0 via openalex
- doi:10.1016/0003-2697(78)90342-1 via openalex
- doi:10.1016/s0736-4679(00)00255-9 via openalex
- doi:10.1016/s0021-9258(19)49767-6 via openalex
- doi:10.1016/s0090-3019(03)00539-1 via openalex
- doi:10.1016/j.fertnstert.2008.10.053 via openalex
- doi:10.1016/j.ejogrb.2010.01.006 via openalex
- doi:10.1056/nejm198501173120305 via openalex
- doi:10.1111/j.1439-0507.1989.tb02293.x via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:17:40.080092+00:00
- unpaywall
- last seen: 2026-09-11T06:32:28.951138+00:00
License: CC0
· commercial use OK